Balanoposthitis

Summary

Balanoposthitis (MONDO:0001618) is a disease with 3 GWAS associations across 6 studies. A subtype of balanitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	balanoposthitis
Mondo ID	MONDO:0001618
DOID	DOID:13031
ICD-10-CM	N47.6
ICD-11	1742248014
SNOMED CT	46090001
UMLS	C0004691
MedGen	507475
Is cancer (heuristic)	no

Data availability: 3 GWAS associations (6 studies).

Disease family

This is a subtype of balanitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › male reproductive system disorder › penile disorder › balanitis › balanoposthitis

Related subtypes (2): balanitis xerotica obliterans, anaerobic balanitis

Subtypes (1): Trichomonas balanoposthitis

Genetics & variants

GWAS landscape

3 GWAS associations across 6 studies. Top hits map to 2 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs146723787	1e-11	RALYL	G	2.65
rs916351393	2e-11	ADAM12	G	1.81
rs373841425	1e-09	LINC03042 - RNF5P1	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90478626	Verma A	2024	2,122	412,216	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478625	Verma A	2024	781	102,842	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480410	Verma A	2024	781	102,842	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478624	Verma A	2024	684	52,179	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651305	Liu TY	2025	339	84,916	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90044261	Jiang L	2021	205	208,603	A generalized linear mixed model association tool for biobank-scale data.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	3

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	2
unknown	1

Functional consequences

Consequence	Count
intron_variant	3

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs146723787	8	84209928	G>A	0	intron_variant	RALYL	1e-11	Tier 4: intronic/intergenic
rs916351393	10	126362448	G>T	0.002	intron_variant	ADAM12	2e-11	Tier 4: intronic/intergenic
rs373841425	8	38540973	G>A,T		intron_variant	LINC03042 - RNF5P1	1e-09	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.